Targeting histone deacetylases in T-cell lymphoma Journal Article

Authors: Moskowitz, A. J.; Horwitz, S. M.
Article Title: Targeting histone deacetylases in T-cell lymphoma
Abstract: Histone deacetylase inhibitors (HDACi) are epigenetic modifiers with single-agent activity in patients with cutaneous and peripheral T-cell lymphoma (CTCL, PTCL). The mechanisms for this preferential activity remain unclear, and although some would term this as ‘class effect,’ there are differences in efficacy and safety, likely a result of the varying chemical structures/classes, histone and non-histone targets, potencies, and clinical dosing for each. Three HDACi have single-agent approval in relapsed/refractory TCL in the United States: romidepsin in CTCL and PTCL, vorinostat in CTCL, and belinostat in PTCL. Although comparison of these agents is difficult due to differences in patient populations, through this review we aimed to provide a detailed overview of the clinical data for HDACi in TCL and their use in clinical practice. Despite early concerns, data demonstrate the cardiac safety of HDACi, while highlighting the need to maintain electrolytes in the normal range and monitor QT interval when initially co-administering antiemetics or other drugs that prolong QT. To further improve response rates and durability of responses, HDACi are under clinical investigation in combination with chemotherapy regimens and various novel agents. © 2016 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
Keywords: vorinostat; t-cell lymphoma; panobinostat; romidepsin; belinostat; chidamide
Journal Title: Leukemia and Lymphoma
Volume: 58
Issue: 6
ISSN: 1042-8194
Publisher: Taylor & Francis Group  
Date Published: 2017-01-01
Start Page: 1306
End Page: 1319
Language: English
DOI: 10.1080/10428194.2016.1247956
PROVIDER: scopus
PUBMED: 27813438
Notes: Review -- Export Date: 4 April 2017 -- Source: Scopus
Altmetric Score
MSK Authors
  1. Steven M Horwitz
    350 Horwitz
  2. Alison Moskowitz
    140 Moskowitz